Physician profile
Jake Dailey
NPI 1447792478
$3,164.55
in general payments reported to CMS, 2019-2025
31 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $674 · 2023: $653 · 2024: $647 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $362.16 | 2021-2025 | Nucala, Shingrix |
| Novo Nordisk INC | $290.27 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $228.07 | 2022-2024 | Dupixent |
| Genzyme Corporation | $179.69 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $174.84 | 2021-2025 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.21 | 2021-2023 | Jardiance |
| Amgen INC. | $141.75 | 2021-2024 | Evenity, Prolia, Otezla |
| Kowa Pharmaceuticals America, INC. | $132.02 | 2021-2024 | Livalo, Seglentis |
| Dexcom, INC. | $107.68 | 2023-2025 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $103.55 | 2021-2025 | Prolastin-C Liquid |
| Esperion Therapeutics, INC. | $103.12 | 2021-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $79.65 | 2021-2022 | |
| Lilly USA, LLC | $76.76 | 2021-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $64.14 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.67 | 2021-2022 | |
| Octapharma USA, INC. | $43.13 | 2024-2025 | Cutaquig |
| Exact Sciences Corporation | $35.58 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $28.82 | 2021 | |
| Axsome Therapeutics, INC. | $20.11 | 2024 | Auvelity |
| Hikma Pharmaceuticals USA | $19.74 | 2025 | Ryaltris |
| Sanofi Pasteur INC. | $19.69 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.32 | 2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.06 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.31 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.95 | 2021 | |
| Ibsa Pharma INC. | $13.52 | 2025 | Tirosint, Licart, Flector |
| Takeda Pharmaceuticals U.S.A., INC. | $12.69 | 2021 | |
| Abbott Laboratories | $12.58 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.